课题基金 / 基金详情

BET bromodomain inhibition as targeted therapy in acute myeloid leukemia

BET bromodomain inhibition as targeted therapy in acute myeloid leukemia
BET 溴结构域抑制作为急性髓系白血病的靶向治疗
批准号:
8635318
负责人:
CHRISTOPHER VAKOC
金额:
$53.26万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-04-01 至 2018-03-31

项目摘要

项目成果

CHRISTOPHER VAKOC的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):该项目的中心目标是了解BRD 4作为急性髓系白血病治疗靶点的作用。作为染色质的调节剂,BRD4是一类新兴的抗癌药物靶点的成员,对其治疗相关的分子功能知之甚少。该提案试图通过确定BRD4在白血病细胞中采用的关键生化机制来解决这个问题,该机制解释了其作为治疗靶点的理想特性。这将包括评估BRD4的哪些区域对其疾病相关功能最关键,以及确定BRD4复合物的关键蛋白质成分,这些蛋白质成分是实验小鼠模型中白血病维持所必需的。还将努力鉴定可以与BRD 4抑制剂协同作用的有效治疗组合,以抑制临床前白血病模型中的白血病进展。该项目将依赖于综合方法,包括生物化学,遗传学,蛋白质组学和表观基因组学策略。这项研究将广泛使用耐化疗性白血病的基因工程小鼠模型,该模型将用于评估BRD 4或其蛋白复合物组分的各种治疗操作的体内功效。总之,这项研究的长期目标将是通过了解这种蛋白质如何作为染色质状态调节剂发挥作用的详细机制,最大限度地提高靶向BRD 4在白血病中的临床益处。
英文摘要
DESCRIPTION (provided by applicant): The central goal of this project is to understand the role of BRD4 as a therapeutic target in acute myeloid leukemia. As a regulator of chromatin, BRD4 is a member of an emerging class of anti-cancer drug targets for which little is understood of its therapeutically-relevant molecular function. This proposal seeks to address this issue by identifying the critical biochemical mechanism employed by BRD4 in leukemia cells that accounts for its desirable properties as a therapeutic target. This will include evaluating which regions of BRD4 are most crucial for its disease-related functions, as well as identifying the key protein constituents of the BRD4 complex that are necessary for leukemia maintenance in experimental mouse models. Efforts will also be made to identify effective therapeutic combinations that can synergize with BRD4 inhibitors to suppress leukemia progression in preclinical leukemia models. This project will rely on integrative approaches, including biochemical, genetic, proteomic, and epigenomic strategies. This research will make extensive use of genetically-engineered mouse models of chemotherapy-resistant leukemia, which will be used to evaluate the in vivo efficacy of various therapeutic manipulations of BRD4 or components of its protein complex. In summary, the long-term goal of this research will be to maximize the clinical benefit of targeting BRD4 in leukemia through an understanding of the detailed mechanism of how this protein works as a regulator of chromatin state.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Elucidating the SCP4 pathway as a multi-catalytic signaling dependency in acute myeloid leukemia
  • 批准号:
    10753227
  • 项目类别:
  • 资助金额:
    $74.25万
  • 财政年份:
    2023
  • 负责人:
    CHRISTOPHER VAKOC
  • 依托单位:
Exploiting POU2F3 addiction in the tuft cell variant of small cell lung cancer
  • 批准号:
    10221648
  • 项目类别:
  • 资助金额:
    $43.92万
  • 财政年份:
    2019
  • 负责人:
    CHRISTOPHER VAKOC
  • 依托单位:
Exploiting POU2F3 addiction in the tuft cell variant of small cell lung cancer
  • 批准号:
    9980811
  • 项目类别:
  • 资助金额:
    $43.92万
  • 财政年份:
    2019
  • 负责人:
    CHRISTOPHER VAKOC
  • 依托单位:
Targeting aberrant enhancer landscapes in pancreatic cancer
  • 批准号:
    10199961
  • 项目类别:
  • 资助金额:
    $41.31万
  • 财政年份:
    2019
  • 负责人:
    CHRISTOPHER VAKOC
  • 依托单位:
海外基金